GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional - and often ineffective - advice to "eat ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

GLP-1 drugs such as Ozempic and Mounjaro have been heralded as some of the most important drug breakthroughs ever.

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

Target RWE, a leader in real-world evidence solutions in liver disease, presented important research on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) among patients with metabolic ...